Neutrophil to Lymphocyte Ratio as a Predictive Factor in Iraqi Patients with Thyroid Cancer

Fatima Falah Hassan; Wafaa Fadhil Hamed; Luma Yousif Mehdi

doi:10.51173/jt.v4i33.780

Authors

Fatima Falah Hassan College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Wafaa Fadhil Hamed College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Luma Yousif Mehdi College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i33.780

Keywords:

Malignant & benign, Thyroid gland, T3, T4, TSH, Neutrophil–lymphocyte ratio

Abstract

Thyroid cancer is one of the fastest growing malignancies in recent years, with an increase of 14.51% per year. It has been shown that there is an association between some biomarkers and the progression of thyroid cancer. In this study, we aim to assess the Neutrophil to Lymphocyte Ratio (NLR) levels and Thyroid function test (TSH, T3, T4) in patients with thyroid cancer. In the current study, (145) participants were divided into 3 groups: G1: (60 malignant thyroid gland patients, G2: (35 benign thyroid gland patients), and G3: (50 healthy control individuals as a control group). The patients attended to AL-Amal oncology Hospital in Baghdad and Imam Sadiq Hospital in Babylon province, Iraq during the period from November 2021 to February 2022. Depending on hematology analyzer the level of NLR and by Mini Vida's the TSH, T3, T4 were estimated in the studied groups. The results showed that the highest number and percentage of malignant thyroid tumors 21 (35%) was among the age group (50-≥ 60) years, while the lowest number and percentage of malignant tumors 10 (16.7%) was among the age groups (20-29) and (30-39) years. The results also demonstrated that the number and percentage of female patients with malignant thyroid tumors was 43 (71.7%) and males 17 (28.3%). A highly significant increase (P<0.01) in the levels of both NLR and TSH was observed in patients with malignant thyroid cancer when compared with their levels in the control group and benign tumor groups. The current study revealed that the age group (50-≥ 60) years and female patients were most affected by thyroid cancer and both NLR and TSH levels were highly increased in thyroid cancer patients. when compared with healthy group.

Downloads

Download data is not yet available.

References

J. Li, B. Zhang, Y. Bai, Y. Liu, B. Zhang, and J. Jin, "Health-related quality of life analysis in differentiated thyroid carcinoma patients after thyroidectomy," Scientific Reports, vol. 10, pp. 1-7, 2020.

R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2019," CA: a cancer journal for clinicians, vol. 69, pp. 7-34, 2019.

T. Kondo, S. Ezzat, and S. L. Asa, "Pathogenetic mechanisms in thyroid follicular-cell neoplasia," Nature Reviews Cancer, vol. 6, pp. 292-306, 2006.

A. Antonelli, E. Baldini, S. Sorrenti, P. Fallahi, P. Miccoli, A. Filippini, et al., "Emerging therapeutic approaches for the most aggressive epithelial thyroid cancers," Thyroid Cancer Advances in Diagnosis and Therapy; InTech: Rijeka, Croatia, pp. 171-191, 2016.

S. Ulisse, E. Baldini, A. Lauro, D. Pironi, D. Tripodi, E. Lori, et al., "Papillary thyroid cancer prognosis: An evolving field," Cancers, vol. 13, p. 5567, 2021.

H. Saffar, S. Sanii, B. Emami, R. Heshmat, V. H. Panah, S. Azimi, et al., "Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors," Pathology-Research and Practice, vol. 209, pp. 195-199, 2013.

L.-L. Huang, Z. Wang, C.-J. Cao, Z.-F. Ke, F. Wang, R. Wang, et al., "AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9," International Journal of Oncology, vol. 51, pp. 812-822, 2017.

E. L. Mazzaferri, "Papillary thyroid carcinoma: factors influencing prognosis and current therapy," Semin in Oncol, vol. 14, pp. 315-332, 1987.

L. Li, J. Wang, Z. Li, S. Qiu, J. Cao, Y. Zhao, et al., "Diagnostic Value of Serum lncRNA HOTAIR Combined with Galectin-3 in Benign and Papillary Thyroid Carcinoma," Cancer Management and Research, vol. 13, p. 6517, 2021.

S. Zeren, İ. Özbay, Z. Bayhan, F. E. Koçak, B. I. Ucar, C. Kahraman, et al., "The neutrophil-to-lymphocyte ratio as a diagnostic marker for malignant thyroid diseases," Turkish Journal of Biochemistry, vol. 42, pp. 559-563, 2017.

H. Moon, J.-L. Roh, S.-w. Lee, S.-B. Kim, S.-H. Choi, S. Y. Nam, et al., "Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy," Radiotherapy and oncology, vol. 118, pp. 330-334, 2016.

G. Liu, L.-c. Ke, and S.-r. Sun, "Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis," Medicine, vol. 97, 2018.

Y. Yu, H. Wang, A. Yan, H. Wang, X. Li, J. Liu, et al., "Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis," BMC cancer, vol. 18, pp. 1-9, 2018.

H. Tang, W. Lu, B. Li, C. Li, Y. Xu, and J. Dong, "Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis," Oncotarget, vol. 8, p. 36857, 2017.

B. Azab, V. R. Bhatt, J. Phookan, S. Murukutla, N. Kohn, T. Terjanian, et al., "Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients," Annals of surgical oncology, vol. 19, pp. 217-224, 2012.

R. A. DeLellis, "World Health Organization classification of tumours," Pathology & Genetics: Tumours of Endocrine Organs, vol. 110, 2004.

H. Fitriyani, T. I. Alferraly, and L. I. Laksmi, "Correlation Between Tsh, T3, T4 and Histological Types of Thyroid Carcinoma," Indonesian Journal of Clinical Pathology and Medical Laboratory, vol. 24, pp. 201-204, 2018.

H. Katoh, K. Yamashita, T. Enomoto, and M. Watanabe, "Classification and general considerations of thyroid cancer," Ann Clin Pathol, vol. 3, p. 1045, 2015.

A. Machens, S. Hauptmann, and H. Dralle, "Disparities between male and female patients with thyroid cancers: sex difference or gender divide?," Clinical endocrinology, vol. 65, pp. 500-505, 2006.

L. Pagano, C. Mele, M. T. Sama, M. Zavattaro, M. Caputo, L. De Marchi, et al., "Thyroid cancer phenotypes in relation to inflammation and autoimmunity," Frontiers in Bioscience-Landmark, vol. 23, pp. 2267-2282, 2018.

Q. Zeng, Z. Liu, Q. Li, and T. Liu, "Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: a meta-analysis," Medicine, vol. 97, 2018.

N. Xu, Y. Jian, Y. Wang, and W. Tian, "Evaluation of neutrophil‑to‑lymphocyte ratio and calcitonin concentration for predicting lymph node metastasis and distant metastasis in patients with medullary thyroid cancer," Molecular and Clinical Oncology, vol. 9, pp. 629-634, 2018.

S. Jiang, X. Zhang, Y. Yang, P. J. Hotez, and L. Du, "Neutralizing antibodies for the treatment of COVID-19," Nature Biomedical Engineering, vol. 4, pp. 1134-1139, 2020.

Z. Chen, K. Raghav, C. Lieu, Z. Jiang, C. Eng, J. Vauthey, et al., "Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer," British journal of cancer, vol. 112, pp. 1088-1097, 2015.

J.-Y. Kim, T. Park, S.-H. Jeong, C.-Y. Jeong, Y.-T. Ju, Y.-J. Lee, et al., "Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas," Endocrine, vol. 46, pp. 526-531, 2014.

D. K. Manatakis, S. Tseleni-Balafouta, D. Balalis, V. N. Soulou, D. P. Korkolis, G. H. Sakorafas, et al., "Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma," International journal of endocrinology, vol. 2017, 2017.

Y. Cho, S.-Y. Kong, A. Shin, J. Lee, E. K. Lee, Y. J. Lee, et al., "Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case–control study," BMC cancer, vol. 14, pp. 1-10, 2014.

J. Jonklaas, H. Nsouli-Maktabi, and S. J. Soldin, "Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer," Thyroid, vol. 18, pp. 943-952, 2008.

M. R. Haymart, D. J. Repplinger, G. E. Leverson, D. F. Elson, R. S. Sippel, J. C. Jaume, et al., "Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage," The Journal of Clinical Endocrinology & Metabolism, vol. 93, pp. 809-814, 2008.

K. Boelaert, "The association between serum TSH concentration and thyroid cancer," Endocrine-Related Cancer, vol. 16, pp. 1065-1072, 2009.